The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia
Open Access
- 1 March 2012
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 122 (3), 935-947
- https://doi.org/10.1172/jci46465
Abstract
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. Long-term survival of patients with AML has changed little over the past decade, necessitating the identification and validation of new AML targets. Integration of genomic approaches with small-molecule and genetically based high-throughput screening holds the promise of improved discovery of candidate targets for cancer therapy. Here, we identified a role for glycogen synthase kinase 3α (GSK-3α) in AML by performing 2 independent small-molecule library screens and an shRNA screen for perturbations that induced a differentiation expression signature in AML cells. GSK-3 is a serine-threonine kinase involved in diverse cellular processes, including differentiation, signal transduction, cell cycle regulation, and proliferation. We demonstrated that specific loss of GSK-3α induced differentiation in AML by multiple measurements, including induction of gene expression signatures, morphological changes, and cell surface markers consistent with myeloid maturation. GSK-3α–specific suppression also led to impaired growth and proliferation in vitro, induction of apoptosis, loss of colony formation in methylcellulose, and anti-AML activity in vivo. Although the role of GSK-3β has been well studied in cancer development, these studies support a role for GSK-3α in AML.Keywords
This publication has 50 references indexed in Scilit:
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Densely Interconnected Transcriptional Circuits Control Cell States in Human HematopoiesisCell, 2011
- DNMT3AMutations in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2010
- GSK-3 Promotes Conditional Association of CREB and Its Coactivators with MEIS1 to Facilitate HOX-Mediated Transcription and OncogenesisCancer Cell, 2010
- Distinct Roles of Glycogen Synthase Kinase (GSK)-3α and GSK-3β in Mediating Cardiomyocyte Differentiation in Murine Bone Marrow-derived Mesenchymal Stem CellsOnline Journal of Public Health Informatics, 2009
- Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinomaBritish Journal of Cancer, 2009
- Proteomic and Genetic Approaches Identify Syk as an AML TargetCancer Cell, 2009
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeThe New England Journal of Medicine, 2009
- Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generationProceedings of the National Academy of Sciences of the United States of America, 2009
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005